Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Disease-Specific Drug Development Guidances Coming From US FDA In 2018

Jan 19 2018

• By Brenda Sandburg

Vintage typewriter with To Do list for 2018

Related Content

REMS Barriers: US FDA Takes 'Foundational Step' To Improve Generic Access

Nov 09 2017

Addiction Recovery Medications' 'Stigma' Needs To Be Eliminated, Gottlieb Says

Oct 26 2017

Refuse-to-File Turns 25: New Guidance Changes In Style, But Not Substance

Jan 12 2018

FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development

Sep 12 2017

Alzheimer's Guidance Coming From US FDA, Part Of Broader OND Reform

Sep 14 2017

Opioid Treatments Could Get Survival Claim As US FDA Develops Protocol

Dec 02 2017

Want To Avoid A Refuse-To-File? Submit ANDA In English, FDA Says

Jan 04 2018

How To Conduct A Multi-Company Trial For Rare Pediatric Diseases

Dec 06 2017

Woodcock Wants Rapid Regulatory Policy Development

May 22 2017

Antibiotic Pipeline Profile: Balancing Broad Spectrum And Limited Use

Jul 05 2017

US FDA's New Hypogonadism Guidance Focuses On Non-Testosterone Products

Jan 04 2018

Pediatric Drug Development A Priority For US FDA’s New Oncology Center Of Excellence

Feb 22 2017

US FDA Progress Report Highlights Biomarkers, Continuous Manufacturing, Antibiotic Testing

Mar 31 2017

DTC Rx Drug Ad Study No. 30: Do Market Claims Impact Perception?

Jul 29 2015

Duchenne Muscular Dystrophy: FDA Supports Broader Outcome Measures, Biomarkers

Jun 10 2015

FDA Ushers In Era of New Drug Manufacturing Technologies

Jun 20 2016

Additional Topics

United States Drug Approval Standards Clinical Trials Generic Drugs Regulation FDA BioPharmaceutical

More from Products

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window